Aligos completes enrollment in Phase 2 B-SUPREME trial for chronic hepatitis B drug pevifoscorvir sodium
ALGS•Next data expected in 2027
Topline safety and efficacy data are expected in late Q3 2027.
Phase 2 trial enrollment completed
Aligos completed enrollment in its Phase 2 B-SUPREME trial of pevifoscorvir sodium for chronic hepatitis B.
Enrollment reached 131 HBeAg+ participants in Part 1a; the planned second interim analysis for sample-size re-estimation was dropped.
Part 2a enrolled 114 HBeAg- participants.
